CCM
XERS icon

CAAS Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

CAAS Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$40K – 622
2020
Q2 		$27K Buy
+10,000
New +$34.8K ﹤0.01% 397

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's XERS Position: Q3 2020 in Review

CAAS Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 10,000 shares — an estimated $40K sold.

CAAS Capital Management first reported a position in XERS in Q2 2020 and held it in 1 quarter. The position peaked at $27K in Q2 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

  • CAAS Capital Management reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 10,000 Xeris Biopharma Holdings shares in Q3 2020, an estimated $40K.
  • CAAS Capital Management first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Xeris Biopharma Holdings position peaked at $27K in Q2 2020.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.